Global Cell Based Assays Market by Growth, Industry Size, Trends, Shares, By Top Players, And Forecast 2033

he cell-based assays market is on a trajectory of sustained growth, driven by technological innovation and the expanding use of biologics in healthcare.

VANCOUVER, BRITISH COLUMBIA, CANADA, January 20, 2025 /EINPresswire.com/ -- The global Cell-Based Assays Market is forecasted to grow from USD 18.21 billion in 2024 to USD 39.56 billion by 2033, achieving a robust compound annual growth rate (CAGR) of 9.00%, according to a recent analysis. Key factors propelling this growth include the increasing demand for biologics, advancements in drug discovery platforms, and the shift toward predictive cellular models.

Rising Demand for Biologics Fuels Market Expansion

Biologics, including vaccines, gene therapies, and recombinant therapeutic proteins, are increasingly being used to treat a variety of diseases. This surge in biologics sales is a major driver for the growth of cell-based assays, which play a critical role in evaluating potency, safety, and biological similarity. For example, in 2021, biologics sales in Canada exceeded $11 billion, highlighting the growing importance of these therapies.

Get Free Sample PDF Copy Of This Report@ https://www.emergenresearch.com/request-sample/3144

Innovation in Drug Discovery Drives Growth

The pharmaceutical industry’s need to minimize costly late-stage drug development failures has accelerated innovation in cell-based assay technologies. These assays provide vital insights during drug discovery, helping reduce risks and improve success rates. A Sigma analysis revealed that late-stage failures could lead to a significant drop in return on investment, with rates potentially falling as low as 5%.

Major advancements in high-content systems and data analytics are enabling researchers to extract more detailed biological data, which aids in making informed decisions during drug development.

Cutting-Edge Platforms Revolutionize Research

Leading companies in the market are leveraging technology to enhance drug discovery. For instance, Selvita, a Poland-based biotechnology firm, launched a novel cell-based phenotypic assay platform in February 2021. Designed to address neuroinflammatory and fibrotic diseases, this platform integrates high-content imaging and artificial intelligence to streamline drug profiling and accelerate research.

Challenges Remain: Costs and Resource Demands

Despite its promising growth, the cell-based assays market faces challenges such as high costs and the resource-intensive nature of research. Developing and validating these assays requires significant investment in equipment, reagents, and skilled professionals, making them less accessible for smaller laboratories and research institutions.

This financial barrier may hinder market growth, particularly in regions with limited funding. Efforts to reduce costs and increase accessibility will be critical to ensuring the broader adoption of cell-based assays across various sectors.

Browse Full Report: https://www.emergenresearch.com/industry-report/cell-based-assays-market

Market Insights: Drug Discovery Leads the Way

The drug discovery segment remains the largest application category in the cell-based assays market, driven by increasing demand for new medications and substantial R&D investments. The rise in chronic diseases such as cancer, cardiovascular disorders, and diabetes has further fueled this segment's growth.

The basic research segment is also expected to grow significantly, as researchers continue to rely on cell-based assays to study disease mechanisms and identify potential therapeutic targets. This segment’s expansion is tied to the growing prevalence of diseases requiring advanced research methods.

The cell-based assays market is on a trajectory of sustained growth, driven by technological innovation and the expanding use of biologics in healthcare. While challenges related to costs and resources persist, advancements in predictive cellular models and drug discovery platforms promise to revolutionize the field, making cell-based assays an indispensable tool in medical research and drug development.

In January 2023, Charles River Laboratories purchased SAMDI Tech, which provides label-free HTS solutions for drug discovery research. The acquisition provided CRL with experience in label-free HTS MS platforms and resulted in a broad library of drug discovery options.

Some of the key companies in the global Cell-Based Assays market include:

BD
Thermo Fisher Scientific Inc.
Danaher Corporation
Merck KGaA
Agilent Technologies, Inc.
Lonza
Charles River Laboratories
Bio-Rad Laboratories, Inc.
Revvity
Sartorius AG
Corning Incorporated
Promega Corporation
Cell Signaling Technology, Inc
Eurofins Scientific
Enzo Biochem, Inc.
Carna Biosciences, Inc.
Intertek Group pic
BICO
Cell Biolabs, Inc
Reaction Biology
AAT Bioquest, Inc.
Pestka Biomedical Laboratories, Inc.
Neuromics
BPS Bioscience, Inc.
BellBrook Labs
Profacgen
BMG LABTECH
Hanugen Therapeutics
Altogen Labs
BioAgilytix

Cell-Based Assays Latest Industry Updates

In April 2024, BD introduced the BD FACSDiscover S8 Cell Sorters to help researchers broaden their study into areas such as cell biology, cancer research, and immunology.

In October 2023, Danaher Corporation (Beckman Coulter Life Sciences) teamed with 10x Genomics to expand automation solutions for single-cell test workflows.

In February 2023, Agilent Technologies, Inc. introduced the CELLigence RTCA HT (real-time cell analysis high throughput) platform, which is compatible with the BioTek BioSpa 8 Automated Incubator.

Request For Discount: https://www.emergenresearch.com/request-discount/3144

Cell-Based Assays Market Segmentation Analysis

By Offering Outlook (Revenue, USD Million; 2020-2033)

Consumables
Reagents
Assay Kits
Reporter Gene Assays
Cell Growth Assays
Second Messenger Assays
Cell Death Assays
Other Assay Kits
Microplates
Cell Lines
Immortalised Cell Lines
Primary Cell Lines
Stem Cell Lines
Probes & Labels
Other Consumables
Instruments
Software
Services

By Technology Outlook (Revenue, USD Million; 2020-2033)

Flow Cytometry
High Throughput Screening
Label-free Detection
Other Technologies

By Application Outlook (Revenue, USD Million; 2020-2033)

Drug Discovery
Toxicity Studies
Pharmacokinetic Studies
Pharmacodynamic Studies
Basic Research
Genetic Studies
Other Applications

By End User Outlook (Revenue, USD Million; 2020-2033)

Pharmaceutical & Biotechnlogy Companies
Contract Research Organizations (CROs)
Academic & Research Institutes

By Geography Outlook (Revenue, USD Million; 2020-2033)

North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Benelux
Rest of Europe
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Rest of Latin America
Middle East and Africa
Saudi Arabia
UAE
South Africa
Turkey
Rest of MEA

Buy Now: https://www.emergenresearch.com/select-license/3144

Eric Lee
Emergen Research
+ +91 90210 91709
email us here
Visit us on social media:
Facebook
X
LinkedIn